Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de 48 meses para evaluar la eficacia a largo plazo de Elocta en la salud de las articulaciones (A-MORE)

18 de septiembre de 2026 actualizado por: Swedish Orphan Biovitrum

Un estudio observacional multicéntrico de 48 meses para evaluar la eficacia a largo plazo de Elocta en la salud de las articulaciones

This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

Haemophilia A is a rare genetic disorder estimated to occur in one out of 10,000 live births, characterized by a deficiency in coagulation factor VIII causing impaired haemostasis and prolonged bleeding episodes. Moderate haemophilia, defined as < 5%, and severe haemophilia, defined as < 1% of normal factor VIII activity result in frequent and spontaneous bleeds into muscles and joints, commonly the elbows, knees, and ankles. Bleeding into joints can cause acute pain and swelling and can result in reduced joint range of motion, long-term cartilage damage and debilitating haemophilic arthropathy. Early use of prophylaxis with factor VIII replacement is recommended following diagnosis of haemophilia A to maintain joint health and prevent joint destruction. However, despite the use of prophylaxis many patients still experience joint bleeds which may lead to joint deterioration over time. The risk of joint bleeds increases with the amount of time spent below certain FVIII trough levels, e.g. 1, 3 or 5 IU/dL. Thus, there is probably a relation between the intensity of the prophylactic treatment regimen and joint health. Elocta is an extended half-life rFVIII product (EHL rFVIII), with a slower clearance as compared to conventional FVIII products. Treatment with Elocta will therefore provide the treater with a greater flexibility for individualizing prophylaxis as compared to conventional FVIII. Higher trough levels can be reached with Elocta without increasing factor usage or injection frequency. The treater can instead choose to reduce the injection frequency or the factor consumption without lowering trough levels.

Patients may limit their physical activities due to fear of bleeding if they are unaware of their current FVIII level. Patient apps and wearables are now available which allow patients to view their predicted FVIII levels, and capture health-related data (such as bleedings, pain, well-being, physical activity levels etc.). This data can be shared with the treating physician supporting the planning to individualize the patient's factor treatment based on current lifestyle, health status and physical activity levels. Florio, a certified medical device used as part of routine clinical practice, is such an app, and the data output and patient feedback on their activity levels and sense of protection while using Florio will be analysed as exploratory objectives in this study.

The main purpose of this study is to evaluate the effectiveness of Elocta on joint health over a long observation period (48 months). The study will also explore the influence on long term joint health of different Elocta prophylaxis regimens leading to different trough levels and if the extent of patients' physical activity levels can be associated with predicted FVIII levels.

Tipo de estudio

De observación

Inscripción (Actual)

427

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Berlin, Alemania
        • Charité-Universitätsmedizin Berlin Campus Virchow Klinikum
      • Bonn, Alemania
        • Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin
      • Frankfurt, Alemania
        • Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum
      • Frankfurt, Alemania
        • Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin
      • Hamburg, Alemania
        • Universitätsklinikum Hamburg-Eppendorf (UKE)
      • Hanover, Alemania
        • Medizinische Hochschule Hannover
      • Hanover, Alemania
        • Werlhof-Institut für Hämostaseologie GmbH
      • Heidelberg, Alemania
        • SRH-Klinikum Heidelberg
      • Mörfelden-Walldorf, Alemania
        • HZRM Hämöphilie Zentrum Rhein Main
      • München, Alemania
        • Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München
      • Riyadh, Arabia Saudita
        • Dr Suliman Al Habib Hospital Riyadh
      • Riyadh, Arabia Saudita
        • King Faisal Specialised Hospital, KFSH Riyadh, Children
      • Riyadh, Arabia Saudita
        • King Faisal Specialist Hospital KFSH, Adults
      • Riyadh, Arabia Saudita
        • Riyadh Military Hospital (P.S.M.C)
      • Brno, Chequia
        • University Hospital Brno
      • Ostrava, Chequia
        • University Hospital Ostrava
      • Prague, Chequia
        • Dept. of Pediatric Haematology and Oncology, University Hospital Motol
      • Ljubljana, Eslovenia
        • University Medical Centre Ljubljana Division of Paediatrics
      • Barcelona, España
        • Sant Johan De Deu
      • Barcelona, España
        • Hospital de la Santa Creu i Sant Pau
      • Barcelona, España
        • Hospital Vall d'Hebron
      • Cruces, España
        • Hospital Universitario Cruces
      • Donostia / San Sebastian, España
        • Hospital Universitario Donostia
      • Murcia, España
        • Hospital Virgen de la Arrixaca
      • Málaga, España
        • Hospital Universitario Carlos Haya
      • Navarro, España
        • Complejo Hospitalario de Navarra
      • Oviedo, España
        • Hospital Universitario Central de Asturias (HUCA)
      • Palma de Mallorca, España
        • Hospital Universitario Son Espases
      • Seville, España
        • Hospital Universitario Virgen del Rocío
      • Vigo, España
        • Hospital Alvaro Cunqueiro
      • Tallinn, Estonia
        • Lastehaigla, Tallinn (Tallinn Children´s Hospital)
      • Tallinn, Estonia
        • The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla
      • Helsinki, Finlandia
        • Helsinki University Central Hospital, New Children Hospital
      • Turku, Finlandia
        • Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic
      • Thessaloniki, Grecia
        • Ippokrateio Hospital Thessaloniki (adult department)
      • Thessaloniki, Grecia
        • Ippokrateio Hospital Thessaloniki (pediatric department)
      • Bari, Italia
        • University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.)
      • Cesena, Italia
        • AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini
      • Genova, Italia
        • Giannina Gaslini Institute
      • Milan, Italia
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      • Parma, Italia
        • University Hospital of Parma, AOUP, Haemophilia Center
      • Rome, Italia
        • Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure
      • Torino, Italia
        • Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita
      • Muscat, Omán
        • The Royal Hospital
      • Groningen, Países Bajos
        • University Medical Center Groningen/UMCG
      • Canterbury, Reino Unido
        • East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital
      • London, Reino Unido
        • Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine
      • Gothenburg, Suecia
        • Hematologimottagning Sahlgrenska
      • Malmö, Suecia
        • Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö
      • Bern, Suiza
        • Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital
      • Lausanne, Suiza
        • Service et Laboratoire central d'hématologie, Adults
      • Sankt Gallen, Suiza
        • Zentrum für Labormedizin
      • Zurich, Suiza
        • Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Patients diagnosed with haemophilia A regardless of severity, of any gender and age, on factor treatment with Elocta according to usual clinical practice.

Descripción

Inclusion Criteria:

  • Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations
  • Have a diagnosis of haemophilia A
  • At enrolment on prophylactic treatment with Elocta, independent of participation in the study

Exclusion Criteria:

  • Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study
  • Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit [BU]/mL) at the latest available inhibitor test

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Hemophilia A patients

All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice.

Extended half-life factor VIII product

Otros nombres:
  • efmoroctocog alfa
  • ELOCTAR
  • rFVIIIFc

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Joint health: Target joint development
Periodo de tiempo: 48 months

Number of target joints

48 months
Joint health: Target joint resolution
Periodo de tiempo: 48 months

Number of resolved target joints

48 months
Joint health: Target joint recurrence
Periodo de tiempo: 48 months

Number of recurring target joints

48 months
Joint health: Annualised joint bleeding rate (AJBR) for treated bleeds
Periodo de tiempo: 48 months

Number of joint bleeding events per year, for treated bleeds

48 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Disease Activity (hypertrophic synovium) and Disease Damage (Cartilage or Bone) scores for elbows, knees and ankles
Periodo de tiempo: 48 months

The Haemophilia Early Arthropathy Detection with UltraSound (HEAD-US) protocol will be used. The total score represents the sum of item scores for abnormalities detected. Its values range from 0 (minimum) to 8 (maximum). A higher score indicates a worse outcome.

48 months
Global Gait Score, and/or joint score items for elbows, knees and ankles.
Periodo de tiempo: 48 months

The Haemophilia Joint Health Score (HJHS) system will be used. Global Gait Score, and/or Joint score items (swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, extension loss, joint pain, strength, gait) for elbows, knees and ankles.

The minimum score per joint is 0, the maximum score is 20. The overall total joint score (range 0-120) is the sum of the 6 six index joint (elbows, knees and ankles) scores. A higher score indicates a worse outcome.

48 months
Joint and physical evaluation for elbows, knees and ankles.
Periodo de tiempo: 48 months

The WFH Physical Examination Score (AKA Gilbert Score) will be used. Joint evaluation (pain, bleeding, physical examination and radiologic evaluation) and physical evaluation (swelling, muscle atrophy, axial deformity, crepitus on motion, range of motion, flexion contracture, and instability). A higher score indicates a worse outcome.

48 months

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Effectiveness of Elocta: Annualised bleeding rate (ABR) for treated bleeds
Periodo de tiempo: 48 months

Number of bleeding events per year, for treated bleeds

48 months
Effectiveness of Elocta: Annualised bleeding rate (ABR) for all bleeds
Periodo de tiempo: 48 months

Number of bleeding events per year, for all bleeds

48 months
Effectiveness of Elocta: Occurrence of zero (0) joint bleeds
Periodo de tiempo: 48 months

Percentage (%) of study population with zero (0) joint bleeds

48 months
Effectiveness of Elocta: Work productivity and impairment
Periodo de tiempo: 48 months

Assessed by WPAI-SHP questionnaire

48 months
Effectiveness of Elocta: Quality of Life
Periodo de tiempo: 48 months

Assessed by Haemo-QoL/Haem-A-QoL questionnaire

48 months
Effectiveness of Elocta: Physical activity level
Periodo de tiempo: 48 months

Assessed by the Saltin-Grimby scale

48 months
Effectiveness of Elocta: Quality of Life
Periodo de tiempo: 48 months

Assessed by EQ-5D-5L/EQ-5D-Y questionnaire

48 months
Effectiveness of Elocta: Severity of joint health
Periodo de tiempo: 48 months

Assessed by Patient Global Impression of Severity of Joint Health questionnaire

48 months
Effectiveness of Elocta: FVIII plasma levels
Periodo de tiempo: 48 months

Percentage (%) of FVIII plasma level

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Periodo de tiempo: 48 months

Assessed by medication dose

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Periodo de tiempo: 48 months

Assessed by total number of exposure days per medication

48 months
Usage of Elocta: Annualised injection frequency per subject
Periodo de tiempo: 48 months

Assessed by prescription

48 months
Usage of Elocta: Annualised factor consumption per subject
Periodo de tiempo: 48 months

Assessed by prescription [IU/kg]

48 months
Usage of Elocta: Adherence
Periodo de tiempo: 48 months

Investigator assessed (Percentage (%))

48 months
Exploratory Objective
Periodo de tiempo: 48 months

Influence of different Elocta prophylaxis regimens on long term joint health

48 months
Exploratory Objective: Impact of florio HAEMO on patients' sense of protection and their activity level
Periodo de tiempo: 48 months

Results from questionnaire on impact of florio HAEMO tools on patients' sense of protection and their activity level

48 months
Exploratory Objective: Explore adherence to prescribed treatment regimen
Periodo de tiempo: 48 months

florio HAEMO captured treatment adherence scores

48 months
Exploratory Objective: Explore relationship between predicted FVIII levels and physical activity
Periodo de tiempo: 48 months

florio HAEMO captured predicted FVIII levels, florio HAEMO captured physical activity (type, duration, heart rate and steps)

48 months
Exploratory Objective: Explore timing of bleeds in relation to predicted FVIII levels and physical activity
Periodo de tiempo: 48 months

florio HAEMO captured bleed data (timing, location, cause, treated/untreated), florio HAEMO captured injection data (time, dose), florio HAEMO captured predicted FVIII levels

48 months
Exploratory Objective: Explore the use of Florio to characterise pain and well-being
Periodo de tiempo: 48 months

florio HAEMO captured pain data (time, location, cause, intensity), florio HAEMO captured well-being data

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months

Target joint development, resolution and recurrence

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months

Annualised joint bleeding rate (AJBR) for treated bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months

Ultrasound (HEAD-US)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months

Clinical joint scoring (HJHS)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months

Annualised bleeding rate (ABR) (based on bleeding episodes assessed according to local practice) for all bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months

Occurrence of zero (0) joint bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months

Quality of Life assessed by Haemo-QoL/Haem-A-QoL

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Periodo de tiempo: 48 months

Physical activity level assessed by the Saltin-Grimby scale

48 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Study Physician, Swedish Orphan Biovitrum

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

30 de marzo de 2020

Finalización primaria (Actual)

4 de mayo de 2026

Finalización del estudio (Actual)

4 de mayo de 2026

Fechas de registro del estudio

Enviado por primera vez

20 de febrero de 2020

Primero enviado que cumplió con los criterios de control de calidad

2 de marzo de 2020

Publicado por primera vez (Actual)

3 de marzo de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • Sobi.Elocta-005

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .